

20 December 2024

Treatment of Non-Small Cell Lung Cancer

I hope you'll be able to help me with an FOI request about lung cancer.

1. How many early-stage (non-metastatic or Stages 2-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq) <5
- Durvalumab (Imfinzi) <5
- Nivolumab (Opdivo) <5
- Pembrolizumab (Keytruda) 9

- **Chemotherapy:**
 - Cisplatin+Vinorelbine 5
 - Gemcitabine+Carboplatin <5
 - Nivolumab+Paclitaxel+Carboplatin <5
 - Pembrolizumab+Paclitaxel+Carboplatin <5
 - Pembrolizumab+Pemetrexed+Carboplatin 8
 - Pemetrexed+Carboplatin <5

- **Radiotherapy:**

136 lung over 3 months, but unable to say whether radical, palliative, small cell or non-small cell as this information is not held.

- **Chemotherapy AND Radiotherapy** 14

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. How many patients has your Trust treated in total in the past 3 months for:

- **Stage 2 Non-Small Cell Lung Cancer**
- **Stage 3 Non-Small Cell Lung Cancer**

This information is not held.

20 December 2024

3. How many patients who received Pembrolizumab for Non-Small Cell Lung Cancer (NSCLC) (any stage) in the last 3 months, received:

Pembrolizumab Monotherapy:

- | | |
|---|----|
| 1. Treatment every 3 weeks (200mg, Q3W) | <5 |
| 2. Treatment every 6 weeks (400mg, Q6W) | 8 |

Pembrolizumab in combination with chemotherapy:

- | | |
|---|----|
| 1. Treatment every 3 weeks (200mg, Q3W) | 7 |
| 2. Treatment every 6 weeks (400mg, Q6W) | <5 |